ARWR · NASDAQ · Biotechnology

Arrowhead Pharmaceuticals (ARWR)

Develops targeted RNAi medicines and markets REDEMPLO for familial chylomicronemia syndrome.

$71.83
After-hours close0.00 (0.00%)
At close$71.83(+4.42%)